RACHEL CUNNINGHAM: Open Payments
NPI 1750370706 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$754 in 35 payments from 22 companies in 2025. Trend: 2023 $643 · 2024 $671 · 2025 $754
Food & beverage: $754
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 3 | $90 |
| AstraZeneca Pharmaceuticals LP | 4 | $84 |
| Novartis Pharmaceuticals Corporation | 4 | $74 |
| PFIZER INC. | 3 | $54 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Celgene Corporation | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $37 |
| E.R. Squibb & Sons, L.L.C. | 2 | $36 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $31 |
| EMD Serono, Inc. | 1 | $28 |
Products named: KEYTRUDA, IBRANCE, REBLOZYL, NINLARO, OPDIVO, LYNPARZA, SCEMBLIX, Nubeqa.
Industry payments across LA — which companies pay providers there.
